Observational studyEpilepsia open2025
A model-based cost-effectiveness estimates of hormonal therapy in Indian children with infantile epileptic spasms syndrome.
Observational study in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and incidence of infantile epileptic spasms syndrome in India: A systematic review and meta-analysis.Epilepsia open · 2026Pooled it
- A model-based cost-effectiveness estimates of hormonal therapy in Indian children with infantile epileptic spasms syndrome.Epilepsia open · 2025Observational
- HMGB1-TLR4 signaling-mediated neuroinflammation contributes to the pathogenesis of infantile epileptic spasms syndrome in rats.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDue to the conflicting evidence and expected regional therapeutic variations for cost-effectiveness in children with infantile epileptic spasms syndrome (IESS), this study assessed treatment effectiveness, safety, Health-Related Quality of Life (HRQoL), and performed a cost-effectiveness analysis (CEA) for hormonal therapies in Indian children with IESS.
methodsThis prospective observational study was conducted at a referral pediatrics center in North India. Children with IESS (aged 3-18 months), who were prescribed either a synthetic form of adrenocorticotrophic hormone (ACTH) or oral prednisolone, were included and compared for cessation of epileptic spasms (ES), treatment-emergent adverse events (TEAEs), HRQoL (assessed through Hi-QUALIN), and cost-effectiveness using a decision-tree model. Incremental cost effectiveness ratio (ICER) and number needed to treat were calculated. One-way sensitivity analyses predicted the impact of each variable on the cost-effectiveness (CE) model using a Tornado diagram.
resultsOf 93 children with IESS [73 (79%) boys; mean age (SD) = 10.1 (3.7) months; median (IQR) daily burden of ES: 27.8 (14.0, 61.9)], 55 (59%) were initiated on ACTH, while the rest on oral prednisolone (38 [41%]). After 2 weeks of treatment, ES cessation was achieved in 29/55 (53%) on ACTH and 13/38 (34%) on oral prednisolone. Additionally, an insignificantly different incidence of TEAEs was reported in the ACTH group (23/55 [42%]) compared with the oral prednisolone group (19/38 [50%]). Children aged 3-12 months showed statistically significant improvement in overall HRQoL scores at 2 weeks of treatment (p < 0.01). Using a decision tree model, CEA showed higher ICER (ICER: 122 185 INR; ~1468.90 USD and QALY: 331 643 INR; ~3987.0 USD) for ACTH than oral prednisolone, suggesting caregiver or parents need to spend at least 122 185 INR for one in five children on ACTH to be ES free compared with prednisolone. SIGNIFICANCE: This analysis suggests ACTH was more cost-effective than oral prednisolone for managing IESS from the Indian patient's perspective. ACTH was also a cost-effective option for short-term quality of life outcomes. PLAIN LANGUAGE SUMMARY: This study looked at two first-line treatment options, that is, ACTH and oral prednisolone, for infantile epileptic spasms syndrome (IESS) at a referral pediatric center in North India. We found that ACTH was more effective than oral prednisolone for epileptic spasm cessation and improved health-related quality of life in the short term. Although ACTH costs more, it was found to be a cost-effective option. These findings can help families and clinicians make better treatment choices based on both health benefits and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.